Patient‐reported outcomes in NRG Oncology RTOG 1010: Phase 3 trial evaluating the addition of trastuzumab to trimodality treatment of HER2 overexpressing esophageal adenocarcinoma

Overview of attention for article published in Cancer (0008543X), March 2026

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (73rd percentile)
Above-average Attention Score compared to outputs of the same age and source (58th percentile)

Mentioned by

twitter: 8 X users

So far, Altmetric has seen 8 X posts from 8 X users, with an upper bound of 84,643 followers.

Trastuzumab addition to trimodality therapy fails to enhance patient-reported outcomes in localized HER2+ esophageal adenocarcinoma. by Kachnic LA, Moughan J (...) Movsas B et 17 al. in Cancer https://t.co/EoxH4vjBQ9 #MedX #MedResearch

RT @JournalCancer: New Phase 3 #ClinicalTrial 📊 Results suggest the addition of trastuzumab to chemoradiation for localized HER2+ esophag…

Check out this publications on PRO results from NRG-RTOG 1010 in HER2 overexpressing esophageal adenocarcinoma. More info ⬇️ https://t.co/D38lfxZj2k

RT @JournalCancer: New Phase 3 #ClinicalTrial 📊 Results suggest the addition of trastuzumab to chemoradiation for localized HER2+ esophag…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 4 additional X posts.